Evidence map›Paper›PMID 41588527›Full record

ArticleClinical epigenetics2026

DNA methylation estimates of immune cell abundance have prognostic potential in triple negative breast cancer.

Sarah Williams, Darren Korbie, Matt Trau, Kelly A Avery-Kiejda, Rodney J Scott, Braydon Meyer, Melissa C Southey, Roger L Milne, Pierre-Antoine Dugué, Susan J Clark and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sarah WilliamsCancer Ecosystems Program, Epigenetics Research Laboratory, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia.
Darren KorbieCancer Ecosystems Program, Epigenetics Research Laboratory, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia.
Matt TrauCentre for Personalised Nanomedicine, The University of Queensland, St Lucia, QLD, 4072, Australia.
Kelly A Avery-KiejdaMolecular Medicine, NSW Health Pathology, New Lambton Heights, NSW, 2305, Australia.
Rodney J ScottMolecular Medicine, NSW Health Pathology, New Lambton Heights, NSW, 2305, Australia.
Braydon MeyerCancer Ecosystems Program, Epigenetics Research Laboratory, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia.
Melissa C SoutheyPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, 246 Clayton Road, Clayton, VIC, 3168, Australia.
Roger L MilnePrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, 246 Clayton Road, Clayton, VIC, 3168, Australia.
Pierre-Antoine DuguéPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, 246 Clayton Road, Clayton, VIC, 3168, Australia.
Susan J Clark *Cancer Ecosystems Program, Epigenetics Research Laboratory, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia. s.clark@garvan.org.au.
Clare Stirzaker *Cancer Ecosystems Program, Epigenetics Research Laboratory, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia. c.stirzaker@garvan.org.au.
Ruth Pidsley *Cancer Ecosystems Program, Epigenetics Research Laboratory, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia. r.pidsley@garvan.org.au.

Funding

Cancer Council NSW RG-24-01National Breast Cancer Foundation IIRS-22-060National Health and Medical Research Council #2010156National Health and Medical Research Council #2017325National Health and Medical Research Council #2026430The Garvan Institute of Medical Research Garvan Support AwardThe University of New South Wales University Postgraduate Award
6 · The paper itself

Abstract

Immune infiltration is now recognised as an important prognostic factor in triple negative breast cancer (TNBC). DNA methylation, due to its cell-type specificity, offers a promising approach for quantifying immune cell abundance as a biomarker for risk stratification. Here, we used EpiDISH, a DNA methylation-based cellular deconvolution method, to estimate immune cell proportions from genome-wide methylation data across four independent breast cancer datasets. We show that increased methylation-estimated immune cell percentage in TNBC patients is associated with improved outcomes. This highlights the potential of DNA methylation-based estimates of cell composition for prognosis in TNBC.

Indexed as

DNA MethylationTriple Negative Breast NeoplasmsBiomarkers, TumorEpigenesis, GeneticFemaleHumansPrognosisBiomarkers, TumorDNA methylationEpigeneticsImmune-cell deconvolutionPrognosisTriple negative breast cancer

Identifiers

PMID41588527
PMCPMC13330045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.